

1 **A Spatial Comparison of Molecular Features Associated with Resistance to** 2 **Pembrolizumab in BCG Unresponsive Bladder Cancer**

3 Khyati Meghani^{1*}, Noah Frydenlund^{1*}, Yanni Yu¹, Bonnie Choy², and Joshua J. Meeks^{1,3*}

4
5 ¹Departments of Urology, and Biochemistry and Molecular Genetics, Northwestern University,
6 Feinberg School of Medicine, Chicago, IL; USA

7 ²Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL;
8 USA

9 ³Jesse Brown VA Medical Center, Chicago, IL USA

10

11 *Equal contribution

12 *Corresponding author:

13 Joshua J. Meeks, joshua.meeks@northwestern.edu; @JoshMeeks, C (312)363-8959

14

15 **Word Count Abstract:**

16 **World Count Manuscript:**

17 **Tables and Figures:**

18 **References:**

19 **Keywords:** Clinical trial, BCG unresponsive, spatial profiling, bladder cancer, pembrolizumab

20

21 **Take Home Message:** We conducted a spatial transcriptomic investigation of BCG
22 unresponsive bladder cancers treated with pembrolizumab and identified distinct expression
23 signatures of the tumor epithelium and tumor microenvironment associated with response or
24 resistance that may be applied in the future to predict response to checkpoint immunotherapy.

25 **Abstract**

26 **Background.** Intravenous immune checkpoint inhibition achieves a 40% three-month response
27 in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ
28 (CIS). Yet only half of early responders will continue to be disease free by 12 months, and
29 resistance mechanisms are poorly defined.

30 **Objective:** We assessed the molecular features associated with response to immunotherapy in
31 BCG unresponsive non-muscle invasive bladder cancers treated with pembrolizumab.

32 **Design, Setting, and Participants:** We performed digital spatial profiling (DSP) of BCG
33 unresponsive NMIBC tumors before and after IV pembrolizumab therapy.

34 **Intervention:** Pembrolizumab was administered intravenously in patients with NMIBC at the
35 time of recurrence after BCG therapy. Biopsies were obtained before starting IV pembrolizumab
36 and three months post-treatment.

37 **Outcomes and Statistical Analysis:** Spatial gene expression profiling of the tumor niche pre-
38 and post IV pembrolizumab.

39 **Results and Limitations:** We evaluated 119 regions of interest (ROIs) from five patients, which
40 included 60 epithelial (PanCK+) and 59 stromal segments (PanCK-). ROIs from responders had
41 distinct expression signatures from non-responders for both the tumor and TME. Responders
42 were more likely to have a dynamic change in expression after pembrolizumab than non-
43 responders. A major limitation of this study was the number of patients evaluated.

44 **Conclusion:** For the first time, we have identified distinct expression signatures associated with
45 response and resistance to IV pembrolizumab in NMIBCs. Further research with more patients
46 and alternative checkpoint inhibitors is essential to validate our findings.

47 **Patient Summary:** We identify the molecular features of tumors associated with response to
48 pembrolizumab for patients with BCG unresponsive NMIBCs.

49 **Introduction**

50 BCG is the primary treatment for high-grade non-muscle invasive bladder cancer
51 (NMIBC). Yet, at least one-third of NMIBCs treated with BCG will not respond and progress to
52 more advanced stages of bladder cancer. In 2020, following the results of KEYNOTE-057^{1,2}, in
53 which 40.6% of patients had a complete response at three months, pembrolizumab
54 monotherapy was approved for use in patients with BCG unresponsive high-risk NMIBC.
55 Unfortunately, response to pembrolizumab is not durable, and overall, 80% of treated patients
56 will have recurred or progressed by 12 months.

57 Since FDA approval, pembrolizumab has become a mainstay in the treatment of BCG
58 unresponsive bladder cancer. Yet, there is limited information on how to best identify patients
59 who will benefit from this course of treatment. The identification of biomarkers that predict
60 response to pembrolizumab could facilitate the selection of NMIBCs, and spare unresponsive
61 patients the unnecessary toxicity associated with immune checkpoint treatment.

62 We have previously performed a multi-omics evaluation of a small Phase I trial of BCG
63 unresponsive NMIBCs treated with BCG and intravesical pembrolizumab³. While this study was
64 primarily focused on mechanisms of tumor response in the unique setting of intravesical
65 administration of pembrolizumab and BCG, we were intrigued to compare this to IV
66 pembrolizumab. To evaluate the response mechanisms of IV pembrolizumab, we performed
67 digital spatial profiling of tumors from responders and non-responders before and after
68 treatment. Our results describe the spatial transcriptomic differences in pre-treatment NMIBCs
69 and offer initial insights to identify individuals who may respond to IV pembrolizumab.

70 **Methods**

71 **Sample identification and collection:** After obtaining institutional review board (IRB) approval,
72 the Northwestern Medicine Enterprise Data Warehouse (EDW) was queried to identify patients
73 with BCG unresponsive NMIBC who were treated with at least three cycles of intravenous
74 pembrolizumab. Patients were selected for inclusion in the study if adequate pre- and post-
75 treatment formalin fixed paraffin embedded (FFPE) bladder biopsies were available in our
76 institutional tissue repository. We identified five patients (three responders and two non-
77 responders, Supplementary Table 1) who met inclusion criteria. FFPE blocks were sectioned at
78 a thickness of 5µm and mounted on slides for DSP analysis. Slides were reviewed by a
79 genitourinary pathologist (BC) to confirm the adequacy of selected biopsies before proceeding
80 with DSP preparations.

81 **Digital Spatial Profiling:** Using methods previously described⁴, slides were deparaffinized by
82 baking in a drying oven at 60°C for two hours, washing in xylene (3 x 5 min), 100% ethanol (2 x
83 5 min), 95% ethanol (2 x 5 min), and 1x PBS (1 x 1 min). Target retrieval was performed by
84 placing the slides into a steamer containing DEPC-water heated to 99°C for 10 seconds
85 followed by 1x Tris-EDTA for 20 minutes. Slides were then washed in 1x PBS (5 min) before
86 incubating in 1µg/mL Proteinase K (Thermo Fisher, Waltham, MA) at 37°C for 20 minutes. Post-
87 fixation was performed by washing in 10% neutral buffered formalin (NBF) for five minutes,
88 followed by NBF stop buffer (0.1M tris, 0.1M glycine in DEPC-treated water, 2 x 5 min), followed
89 by 1x PBS (1 x 5 min). RNA probe library *in situ* hybridization was performed using the
90 NanoString GeoMX™ Whole Transcriptome Atlas (WTA) (NanoString, Seattle WA) which was
91 diluted per manufacturer instructions to create hybridization solution. Hybridization solution was
92 applied to each slide which then covered with Grace Bio-Labs Hybrislip™ (Bend, OR)
93 hybridization covers. Slides were incubated in a hybridization oven at 37°C for 20 hours. Next,
94 off target probes were removed by performing stringent washes (100% formamide in equal parts
95 4X-SSC) at 37°C (2 x 25 min) followed by 2X SSC wash at room temperature (2 x 2 min). Slides
96 were then placed into a humidity chamber at room temperature and blocked using blocking
97 buffer W (NanoString, Seattle, WA) for 30 minutes. To facilitate identification of the tumor and
98 TME slides were next stained with immunofluorescent antibodies from the NanoString solid
99 tumor TME morphology kit [Pan-CK for epithelial cells, CD45 for immune cells, and SYTO 83 for
100 nuclear staining] (NanoString, Seattle, WA) for one hour.

101 DSP was then performed on prepared slides using the GeoMx digital spatial profiler
102 (NanoString, Seattle, WA). After loading and scanning the slides onto the instrument a total of

103 60 regions of interest (ROIs) were manually selected for transcriptomic profiling. Each ROI was
104 divided into two segments based on the presence of immunohistochemical morphologic
105 markers, with PanCK+ staining areas analyzed as tumor segments and PanCK- segments
106 analyzed as stroma. Photocleaved DNA oligonucleotides were aspirated from each segment
107 separately and stored in an individual well in a 96-well plate. Per the default NanoString
108 GeoMx™ protocol, Illumina i5 and i7 dual indexing primers were added to the oligonucleotide
109 tags during PCR, uniquely indexing each segment. AMPure XP beads (Beckman Coulter,
110 Indianapolis, IN) were used for PCR purification. Library concentration was measured using a
111 Qubit fluorometer (Thermo Fisher, Waltham, MA) and quality was assessed using a Bioanalyzer
112 (Agilent Technologies Inc., Santa Clara, CA). Sequencing was performed on an Illumina
113 NovaSeqX (Illumina Inc., San Diego, CA). After sequencing, reads were trimmed, stitched,
114 aligned, and de-duplicated. Fastq files were converted to DCC files using the GeoMx NGS
115 Pipeline v2.3.3.10, which were then loaded onto the GeoMx instrument and converted into
116 target counts for each segment. Raw counts were filtered based on two criteria : to remove
117 targets detected below the limit of quantitation (LOQ), and to remove segments with fewer than
118 50 nuclei. Filtered raw counts were Q3 normalized for comparison across all segments and
119 were used for further analysis.

120 **Bioinformatics and Data Visualization:** All analyses were performed in R v4.2.3. Principal
121 component analysis was performed using PCAtools v2.10.0. Heatmaps were generated using
122 ComplexHeatmap v2.14.0. Differential expression analysis was performed using limma v3.54.2.
123 Volcano plots were generated using ggplot2 v3.4.4. Pathway analysis was conducted using
124 msigdb⁵ gene sets downloaded using msigdbR v7.5.1 package and analyzed using fgsea
125 v1.24.0. Gene signatures for the intravesical cohort were generated by comparing PanCK and
126 Stroma specific expression profiles between responders and non-responders. Similarly, cluster-
127 specific gene signatures for the PURE01 cohort⁶ were generated by comparing each cluster to
128 the rest. Enrichment of these gene sets within the current IV pembrolizumab cohort was tested
129 using the GSEA function, and GSEA plots were generated using the gseaplot function in
130 clusterProfiler v4.6.2. Exhaustion score was calculated as a mean expression of PDCD1,
131 HAVCR2, LAG3, CTLA4, and TIGIT genes. Inflammation score was generated as a mean
132 expression of genes within the msigdb Hallmark Interferon alpha and Interferon gamma
133 response gene sets⁵. Immune deconvolution of the stromal segments was performed using
134 SpatialDecon v1.8.0. Immune Infiltration score was generated as a sum of the different immune

135 cell types (T/NK cells, B cells, myeloid cells, neutrophils, and mast cells) identified by immune
136 deconvolution.

137

138 **Results**

139 ***Cohort***

140 We have previously performed bulk RNA sequencing to identify expression signatures of CPI-
141 treated tumors across multiple cohorts⁶. Yet, due to the limited size of the tumor epithelium in
142 NMIBCs with CIS in which tumors are a few cell layers we hypothesized that bulk RNA-seq
143 might lack the resolution required to dissect the granular details of the tumor/TME in this setting.
144 Therefore, in this study, we performed spatial profiling of tumor sections before and after
145 intravenous pembrolizumab to identify 1) pre-treatment features associated with response or
146 resistance and 2) describe how IV pembrolizumab alter the tumor/TME interaction in BCG
147 unresponsive NMIBCs. Five patients treated with IV pembrolizumab were evaluated: three non-
148 responders and two responders. The demographics and clinical history of the cohort are listed
149 in Supplementary Table 1.

150 ***Spatial Transcriptomic Analysis***

151 A total of 119 Areas of Interest (AOIs) were profiled across five patients at two treatment time
152 points (pre- and post-treatment), capturing 60 tumor (PanCK+) and 59 stromal (PanCK-)
153 segments. As depicted in **Figure 1A**, the application of DSP technology enabled precise
154 delineation, revealing distinct segregation of PanCK and Stromal segments within the tumor
155 microenvironment. Examining differential gene expression between tumoral and stromal
156 segments, we found elevated levels of keratins (KRT7 and KRT19) within the PanCK+
157 segments. Conversely, PanCK- segments exhibited increased expression of stromal (ACTA2,
158 COL1A1, COL4A1, COL6A1) and immune markers (IGHG4, IGHG2). The enrichment of
159 expected epithelial markers (keratins) in PanCK+ segments, and stromal markers (collagens) in
160 the stromal segments validates the quality of transcriptomic data obtained in this study. Further,
161 this molecular characterization offers valuable insights into the unique profiles of PanCK+ and
162 PanCK- segments, identifying dynamic molecular landscape in BCG unresponsive high-grade
163 NMIBCs (**Figure 1B**).

164 165 ***Characteristics of PanCK+ tumor segments that are predictive of response and Impact of*** 166 ***therapy on gene expression in PanCK+ tumor segments.***

167 The reported response to pembrolizumab in BCG unresponsive bladder NMIBCs is 40%
168 at three months. To identify expression signatures of the tumor segments that may affect the
169 treatment response, we first characterized the 60 PanCK+ AOIs. Comparing the expression of
170 canonical bladder cancer subtype markers across the cohort (**Figure 2A**), we identified elevated

171 levels of claudin-low and squamous differentiation markers in pre-treatment PanCK+ segments
172 from responders. In contrast, pre-treatment PanCK+ AOIs from non-responders were enriched
173 for luminal markers. Claudin-low tumors have been previously identified to be immune infiltrated
174 with an expression profile predicted to respond to immune checkpoint blockade⁷.

175 We identified minimal heterogeneity of AOIs from each patient. Comparing the
176 distribution of PanCK+ segments, we find that the expression profile of pre-treatment
177 responders formed a distinct cluster independent of the rest of the cohort (**Figure 2B**). Analysis
178 of pre-treatment PanCK+ AOIs revealed distinctive gene programs associated with treatment
179 response or resistance. Specifically, pre-treatment PanCK+ segments from responders
180 demonstrated elevated inflammation-related pathways, including significant upregulation of
181 genes related to interferon-alpha and gamma response, TNF-alpha signaling, and the IL6-JAK-
182 STAT signaling pathways. (**Figure 2C**). These findings suggest a heightened inflammatory
183 tumor epithelium within the pre-treatment responder segments. In contrast, PanCK+ segments
184 from non-responders had repressed inflammation pathways. Similar to “immune-excluded”
185 tumors, the tumor epithelium had elevated markers of TGF-beta signaling, p53 pathway genes,
186 and estrogen response. (**Figure 2C**).

187 We recently described a transcriptome-based evaluation of the response to immune
188 checkpoint inhibitors in muscle-invasive bladder cancer⁶. We hypothesized that the underlying
189 mechanisms of pembrolizumab activity may remain consistent in early-stage bladder cancer. To
190 test this hypothesis, we applied the five gene signatures described by Robertson et al to tumor
191 AOIs within this cohort⁶. We find Cluster1-MIBC-CPI signatures which were associated with
192 resistance to pembrolizumab (15% complete response) and enriched in luminal immune cold-
193 MIBC tumors with FGFR3 mutations, to be upregulated in pre-treatment PanCK+ segments
194 from non-responders in this cohort. Robertson et al. found Clusters 2 and 3-MIBC-CPI were
195 associated with immune infiltration and a favorable response to immunotherapy (63% complete
196 response)⁶. We find Cluster3 and Cluster2-MIBC-CPI signatures upregulated in pre-treatment
197 PanCK+ segments from responders in the IV pembrolizumab cohort (**Figure 2D and Supp Fig**
198 **1A**). Collectively, this suggests that the CPI clusters may be conserved in the tumor epithelium
199 across stage.

200 We were interested in the dynamic changes caused by pembrolizumab. Spatial profiling
201 of longitudinally collected specimens pre- and post-therapy allowed us to isolate the impact of
202 therapy on the tumor epithelium and the TME separately. By PCA, PanCK+ AOI segments from
203 non-responders (both pre-and post-treatment) clusters closely, highlighting the minimal impact
204 of treatment on the transcriptomes. The limited change in gene expression diverges from the

205 drastic expression changes found in responsive tumors after treatment (**Figure 2B**).
206 Specifically, 807 genes were differentially regulated in responsive tumors, compared to only 22
207 in non-responsive tumors (**Fig 3A**). To identify the gene sets that change in response to
208 pembrolizumab, we compared PanCK+ segments pre-treatment to those collected post-
209 treatment. As seen in **Figure 3B**, post-treatment PanCK+ segments from responders showed a
210 net increase in inflammation-related pathways. In contrast, post-treatment PanCK+ segments
211 from non-responders had a decrease in inflammatory pathways in response to pembrolizumab,
212 including TNF α -signaling, IFN γ response, and IL6-JAK-STAT3 signaling (**Figure 3B**). Overall,
213 our analysis indicates that PanCK+ segments exhibiting signs of inflammation before IV
214 pembrolizumab administration may display enhanced responsiveness to this therapy.

215

216 ***Characteristics of PanCK- stromal segments that are predictive of response.***

217 We next profiled the features of the tumor microenvironment (TME) that could contribute
218 to responsiveness to pembrolizumab. As seen in **Figure 4A**, the pre-treatment TME areas of
219 interest (AOIs) from responders cluster separately from non-responders. Comparing the gene
220 expression programs, we find inflammatory markers such as IFN γ and IFN α strongly
221 upregulated in the pre-treatment stromal AOIs from responders. In comparison, non-responder
222 PanCK- AOIs had upregulation of EMT, myogenesis, angiogenesis, and coagulation gene sets
223 (**Figure 4B**). We utilized immune deconvolution to identify individual immune cell populations
224 within each stromal AOI. TMEs from responders had elevated levels of neutrophils, T cells, and
225 NK cells in the tumor microenvironment relative to non-responders (**Figure 4C**). In response to
226 treatment, we observed an increase in the myeloid cell population in responders and a decrease
227 in non-responders (**Figure 4C**).

228 Pembrolizumab is an immune checkpoint blocking antibody and its efficacy partly relies
229 on the expression of PD-1 on the immune cell surface. Overexpression of PD-1 on the cell
230 surface is a well-established marker of T-cell exhaustion. To understand the functional state of
231 immune cells inhabiting the stromal compartment, we compared expression of exhaustion
232 markers across the different conditions and identified elevated levels of this gene set in the pre-
233 treatment stromal compartment from responders relative to non-responders (**Figure 4D**).
234 Interestingly, we found a minor but significant decrease in the exhaustion score in responders
235 post-treatment. However, this contrasted with an increased exhaustion score observed in non-
236 responders (**Figure 4D**). Previous work from our group has focused on studying tumor-immune
237 dynamics associated with response to intravesical BCG and pembrolizumab combination
238 therapy³. We applied stromal gene signatures that predicts response or resistance to BCG and

239 pembrolizumab and we were able to validate these two pre-treatment signatures in tumors
240 treated IV pembrolizumab. **(Figure 4E).**

241

242 ***Comparison of response strategies for high-risk non-muscle invasive bladder cancer.***

243 Using the same platform, our group previously described the spatial comparisons of the
244 first-in-human administration of BCG and intravesical pembrolizumab³. Given this cohort's
245 unique administration of pembrolizumab, we wanted to evaluate the differences in urothelial
246 gene expression profile between intravesical pembrolizumab and BCG compared IV
247 pembrolizumab. One of the significant benefits of the Digital Spatial Profiling platform is the
248 ability to assay the tumor and stroma segments in physical proximity. We measured if the
249 correlation between the inflammation levels of the PanCK+ segments and the immune
250 infiltration levels of the neighboring stromal segments in pre-treatment AOIs are different
251 between responders and non-responders between the two cohorts. As seen in **Figure 5A**,
252 responders to the combination intravesical therapy exhibited low levels of inflammation in the
253 PanCK+ segments and high levels of infiltration in the neighboring stromal segments. However,
254 responders to the IV pembrolizumab monotherapy showed high levels of inflammation in the
255 pre-treatment PanCK+ segments and high levels of immune infiltration in the adjacent stroma.

256 Consistent with these differences, we tested the PanCK+ signatures generated in the
257 intravesical study to determine if they can assess response in the tumors treated with IV
258 pembrolizumab. As anticipated, we find that the PanCK+ signature that predicts response in the
259 intravesical pembrolizumab and BCG cohort identified non-responders in the pembrolizumab IV
260 cohort, and the PanCK+ signature that predicts lack of response in the intravesical combination
261 therapy cohort are enriched in responders in the pembrolizumab monotherapy cohort **(Figure**
262 **5B).**

263 This comparison suggests that response to IV pembrolizumab is related to inflammation
264 in the tumor and TME. Overall, our findings suggest tumor segments that are inflamed before
265 therapy might benefit more from IV pembrolizumab, whereas pre-treatment non-inflamed BCG
266 unresponsive tumors might be a better candidate for treatment with a combination therapy of
267 BCG and pembrolizumab.

268

269 **Discussion**

270 From the time of the initial reports on immune checkpoint inhibitor efficacy,
271 immunotherapy has been utilized to manage bladder cancers from early to metastatic stages⁸.
272 Overall, the response rate to CPIs in metastatic urothelial cancer is ~20%, with patients

273 expressing PDL1/PD1 more likely to have a more durable response, a stratified HR 0.68, 95%
274 CI 0.43–1.08 compared to chemotherapy^{9,10}. In early-stage BCG unresponsive NMIBC, a similar
275 response was described for patients with CIS, with or without papillary tumors in
276 KEYNOTE057^{1,2} and SWOG S1605¹¹. These results suggest similar drug activity and provide a
277 rationale for identifying the specific patients who might benefit long-term from CPI. In this report,
278 we attempt to profile early-stage NMIBCs to identify response mechanisms to CPI. Despite the
279 frequency of BCG unresponsive BCa, few patients are cured (NED for > 24 months). Yet, the
280 tail of response appears stable for <20% of patients with pembrolizumab. Our goal with this
281 investigation was to identify pre-treatment features associated with response or lack thereof.

282 We evaluated the tumor and TME of responders and non-responders and identified pre-
283 treatment immune signatures associated with response to IV pembrolizumab. We validated
284 signatures generated from PURE01-CPI trial and the intravesical BCG and pembrolizumab trial.
285 Our data confirms that resistance to pembrolizumab is a consequence of limited immune
286 infiltration into the tumor microenvironment^{3,6,12}. It is notable that the pre-treatment signature
287 predictive of response to IV pembrolizumab in BCG unresponsive disease seen here (inflamed
288 tumor epithelium and infiltrated stroma) differs from our previous work with combination
289 intravesical BCG and pembrolizumab (non-inflamed tumors had better response). Given the
290 sequences of therapy in these two studies (BCG failure followed by IV pembrolizumab vs BCG
291 failure followed by simultaneous administration of intravesical BCG and pembrolizumab), it is
292 possible that most of the benefit from BCG involves inducing an inflammatory anti-tumor
293 response where none is present, while pembrolizumab ‘releases the breaks’ on an already
294 present yet ineffective inflammatory response from previous BCG. Lastly, our results suggest
295 that the immune response to pembrolizumab is conserved across bladder cancer stages.

296 Our findings strongly highlight the need to assay the transcriptomic state of the BCG
297 unresponsive tumors prior to deciding the course of treatment. We anticipate that the application
298 of an expression-based biomarker such as the one described here has the potential to identify
299 tumors that are likely to respond to pembrolizumab. Further evaluation of more patients treated
300 with different CPIs is needed to refine our results.

301

302 **Conclusion**

303 We performed a spatial-based evaluation of tumors treated with pembrolizumab. We
304 identified distinct expression signatures associated with the response and resistance of the
305 tumor and TME. Future studies evaluating the accuracy of these signatures will help validate
306 our findings and facilitate biomarker application in patients with NMIBC.

307

308 **Financial Disclosures:**

309 KM: None

310 BC: None

311 YY: None

312 NF: Research Funding from the AUA Foundation

313 JM advisory board/consulting: Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium,

314 Imvax, Pfizer, Seagen/Astellas, Ferring; Research Funding: VHA, NIH, DoD, Compensation for

315 talks/educational courses: AUA, OncLive, Olympus, UroToday; Clinical Trials: SWOG,

316 Genentech, Merck, AstraZeneca

317

318 **Acknowledgments:** None

319

320 **Funding Support/Role of the Sponsor.** This study was funded by the Merck Investigator

321 Studies Program (MISP) and the Robert H. Lurie Cancer Center. JM is supported by grants

322 from the VHA BX005599 and BX003692. This work was supported by the Northwestern

323 University RHLCCC Flow Cytometry Facility and the Cancer Center Support Grant (NCI

324 CA060553).

325

326 **References:**

327 1. Balar, A. V. *et al.* Pembrolizumab monotherapy for the treatment of high-risk non-muscle-

328 invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm,

329 multicentre, phase 2 study. *Lancet Oncol.* **22**, 919–930 (2021).

330 2. Boormans, J. L. *et al.* Updated follow-up from KEYNOTE-057: Phase 2 study of

331 pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder

332 cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG). **19**, e1173–e1174 (7AD).

333 3. Meghani, K. *et al.* First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune

334 Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. *Eur. Urol.* **82**, 602–

335 610 (2022).

336 4. Merritt, C. R. *et al.* Multiplex digital spatial profiling of proteins and RNA in fixed tissue. *Nat.*

337 *Biotechnol.* **38**, 586–599 (2020).

- 338 5. Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set
339 collection. *Cell Syst.* **1**, 417–425 (2015).
- 340 6. Robertson, A. G. *et al.* Expression-based subtypes define pathologic response to
341 neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. *Nat. Commun.*
342 **14**, 2126 (2023).
- 343 7. Kardos, J. *et al.* Claudin-low bladder tumors are immune infiltrated and actively immune
344 suppressed. *JCI Insight* **1**, e85902 (2016).
- 345 8. Meeks, J. J. *et al.* Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and
346 Biomarker Selection. *Eur. Urol.* **84**, 473–483 (2023).
- 347 9. Cubelli, M., Nunno, V. D., Karim Rihawi & Massari, F. Immune checkpoint inhibitors for
348 metastatic bladder cancer. *Transl. Cancer Res.* **6**, (2017).
- 349 10. Galsky, M. D. *et al.* Atezolizumab with or without chemotherapy in metastatic urothelial
350 cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *The Lancet*
351 **395**, 1547–1557 (2020).
- 352 11. Black, P. C. *et al.* Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-
353 unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. *Eur. Urol.* **84**,
354 536–544 (2023).
- 355 12. Mariathasan, S. *et al.* TGF β attenuates tumour response to PD-L1 blockade by
356 contributing to exclusion of T cells. *Nature* **554**, 544–548 (2018).

357

358

359

360

361

362

363

364

365


366

367

368 **Figures**

369

370 **Figure 1:**



371

372

373 **Figure 1:**

374 **A)** Principal component analysis visualizing distribution of AOIs in the cohort.

375 **B)** Volcano plot depicting differential expressed genes between PanCK+ tumor and PanCK-
376 stroma segments.

377

378

379

380

381

382

383

384

385

386


387

388

389

390
391
392

Figure 2:



393
394
395
396
397
398
399
400


Figure 2:

- A)** Heatmap illustrating gene expression patterns across bladder cancer subtypes within PanCK segments.
- B)** Principal Component Analysis (PCA) plot showing the distribution and relationships among PanCK segments in the cohort.
- C)** Heatmap highlighting genes and pathways significantly enriched in pre-treatment PanCK segments, distinguishing responders from non-responders.

401 **D)** Gene Set Enrichment Analysis (GSEA) plot showcasing the enrichment of PURE01 gene
 402 signatures in PanCK segments and comparing responders to non-responders.

403

404 **Figure 3:**



405

406


407 **Figure 3:**

408 **A)** Volcano plot comparing gene expression profiles between pre-treatment and post-treatment
 409 PanCK+ segments from responders and non-responders.

410 **B)** Bar plot highlighting pathways changing in responders and non-responders pre-to-post
 411 treatment.

412
413
414
415

Figure 4:




416
417
418
419
420
421
422
423
424
425
426
427
428
429

Figure 4:

- A)** Principal component analysis visualizing distribution of Stromal AOs in the cohort.
- B)** Heatmap highlighting pathways significantly enriched in pre-treatment stromal segments from responders and non-responders.
- C)** Violin boxplots comparing cellular abundance of specified immune populations within the indicated conditions.
- D)** Violin boxplots comparing exhaustion scores between responders and non-responders in both pre-and post-treatment samples.
- E)** GSEA plot showing the enrichment of stromal gene signatures generated in the intravesical cohort in differentially expressed genes from stromal segments from the IV pembrolizumab cohort comparing responders to non-responders.

430
431
432
433

Figure 5:



434
435
436
437
438
439
440
441
442

Figure 5:

- A)** GSEA plot showing the enrichment of stromal gene signatures generated in the intravesical cohort in differentially expressed genes from stromal segments from the IV pembrolizumab cohort comparing responders to non-responders.
- B)** Correlation plot comparing inflammation score for PanCK segments and infiltration score in the neighboring Stromal segments between responders and non-responders for the intravesical BCG+Pembrolizumab and IV Pembrolizumab Cohort.